Table 3. Clinical Characteristics According to PD-L1 rs4143815 and rs2282055.
| Characteristics | rs4143815 | rs2282055 | ||||||
|---|---|---|---|---|---|---|---|---|
| No. of Patients (N = 50) (%) | No. of Patients (N = 50) (%) | |||||||
| C/C | C/G | G/G | P* | A/A | A/C | C/C | P* | |
| Median Age (Range) | 64.8 (42–78) | 64.1 (40–80) | 67.3 (54–77) | n.s. | 68.4 (54–74) | 63.6 (40–78) | 64.9 (41–80) | n.s. |
| Sex | ||||||||
| Male | 11 | 17 | 6 | n.s. | 6 | 16 | 12 | n.s. |
| Female | 4 | 6 | 6 | n.s. | 4 | 4 | 8 | n.s. |
| PS | ||||||||
| 0–1 | 15 | 23 | 12 | n.s. | 10 | 20 | 20 | n.s. |
| 2–3 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Histology | ||||||||
| Adeno | 13 | 15 | 12 | n.s. | 8 | 16 | 13 | n.s. |
| EGFR-mutated | 6 | 4 | 3 | n.s. | 3 | 4 | 6 | n.s. |
| Squamous | 2 | 8 | 0 | n.s. | 2 | 3 | 5 | n.s. |
| Stage | ||||||||
| I or II | 0 | 0 | 0 | 0 | 0 | 0 | ||
| IIIB/IV | 15 | 23 | 12 | n.s. | 10 | 20 | 20 | n.s. |
| Treatment Line | ||||||||
| First | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Second | 5 | 2 | 3 | n.s. | 2 | 1 | 7 | n.s. |
| ≥Third | 10 | 21 | 8 | n.s. | 8 | 19 | 13 | n.s. |
| Treatment Response | ||||||||
| PR | 4 | 4 | 0 | 0 | 3 | 5 | ||
| SD | 3 | 9 | 4 | 4 | 5 | 7 | ||
| PD | 8 | 10 | 8 | 6 | 12 | 8 | ||
| ORR, % | 36 | 17 | 0 | 0.0319 | 0 | 15 | 25 | 0.0339 |
| DCR, % | 47 | 57 | 33 | n.s. | 40 | 40 | 60 | n.s. |
Abbreviations: PS, performance status; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate; n.s, not significant.
P values indicate whether the group is equally distributed across the subcategories using analysis of variance, and Cochrane-Armitage test, where appropriate.